Terns Pharmaceuticals Reports Shareholder Vote Matter
Ticker: TERN · Form: 8-K · Filed: Jun 16, 2025 · CIK: 1831363
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
TL;DR
Terns Pharma had a shareholder vote on 6/11, details to come.
AI Summary
Terns Pharmaceuticals, Inc. filed an 8-K on June 16, 2025, reporting on a matter submitted to a vote of its security holders on June 11, 2025. The filing does not disclose the specific details of the vote or the outcome.
Why It Matters
This filing indicates a significant corporate action or decision was put to a shareholder vote, the details of which will be important for investors to understand.
Risk Assessment
Risk Level: medium — The filing is a procedural update about a shareholder vote, but the lack of detail on the vote's subject and outcome introduces uncertainty.
Key Players & Entities
- Terns Pharmaceuticals, Inc. (company) — Registrant
- June 11, 2025 (date) — Date of earliest event reported
- June 16, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- Foster City, California (location) — Principal Executive Offices
FAQ
What was the specific matter submitted to a vote of Terns Pharmaceuticals' security holders on June 11, 2025?
The filing does not specify the exact matter that was submitted to a vote of security holders on June 11, 2025.
What was the outcome of the shareholder vote on June 11, 2025?
The filing does not disclose the outcome or results of the shareholder vote that occurred on June 11, 2025.
When did Terns Pharmaceuticals file this Form 8-K?
Terns Pharmaceuticals filed this Form 8-K on June 16, 2025.
What is the principal executive office address for Terns Pharmaceuticals?
The principal executive office address for Terns Pharmaceuticals is 1065 East Hillsdale Blvd., Suite 100, Foster City, California, 94404.
What is the Commission File Number for Terns Pharmaceuticals?
The Commission File Number for Terns Pharmaceuticals is 001-39926.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 16, 2025 regarding Terns Pharmaceuticals, Inc. (TERN).